Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies | Biogen
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease | Nature
Biogen CEO on FDA approval for its Alzheimer's drug - YouTube
Aduhelm safety: the data gap on aducanumab's brain swelling side effect
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients | Reuters
FDA changes prescribing instructions to limit use of contentious Alzheimer's drug amid public backlash | KTLA
Biogen gives up seeking European approval for aducanumab - Drug Discovery and Development
June 7, 2021: A Historic Day | The Long and Winding Road...
The Future of Alzheimer's Treatment? Approval of Aduhelm & Other Anti-Amyloid Antibodies – Montgomery County Medical Society
EMA gives thumbs down to Biogen's Alzheimer's drug aducanumab - Drug Discovery and Development
Congressional Probe of Alzheimer's Drug Approval Finds Fault With FDA Actions | MedPage Today
/cloudfront-us-east-2.images.arcpublishing.com/reuters/YOZVWDX35VKEVCOQV4LDNO3ZTQ.jpg "U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day\" for patients | Reuters")
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients | Reuters
Congressional Investigation into Alzheimer's Drug Aduhelm Faults the F.D.A. and Biogen - The New York Times
James Deardorff on X: ""Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease" - Hmm... 1. https://t.co/k7Ga4ja0br 2. https://t.co/5cr8gYW72s https://t.co/7NboyUVjWr" / X
FDA approves Aduhelm, first new drug for Alzheimer's in 20 years, despite questions - CBS News
Biogen is ready to roll on lecanemab production, CFO says
FDA Approval of a New Alzheimer's Drug Comes With Controversy | Smart News| Smithsonian Magazine
EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING
After disastrous start to launch, Biogen still expects 'minimal' sales from Aduhelm this year | Fierce Pharma
FDA approves much-debated Alzheimer's drug panned by experts | AP News
Aducanumab: will Biogen's Aduhelm recover from its rocky start? - Pharmaceutical Technology
Early Access Programs | Biogen
Controversial FDA Approval Of Alzheimer's Drug Aducanumab Sets Stage For Possible Medicare Coverage Battle
Medicare Finalizes Limits on Aducanumab Coverage | MedPage Today
Biogen stuns with planned US FDA filing for previously scrapped Alzheimer's drug | S&P Global Market Intelligence
